Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF5993 HFA-152a versus HFA-134a safety trial in adults with controlled asthma
NL-OMON58907Phase 3Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in asthma (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Relative change from pre-dose in FEV1 at 10 minutes post-dose on Day 1. Started Jun 2024; status: completed.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON58907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58907.